How to Create a Psychiatric Medication Intake Form for Psychiatric Medication Management (with Free Template)
This guide walks a psychiatric medication-management practice through the ten substantive steps of building an intake form. The result is a delivery-ready packet covering prescriber credential disclosure (state license, NPI, DEA, state controlled- substance certification), the psychotropic informed consent block under the American Psychiatric Association Practice Guideline framework, the FDA black-box warning acknowledgment for each medication carrying one (especially the suicidality warning for under-25 patients on antidepressants and SNRIs), DEA Schedule II prescribing protocol with PDMP query consent, the Ryan Haight Act and 2023 DEA telehealth final rule for controlled substances, the lab monitoring schedule acknowledgment for lithium, valproate, clozapine, and atypical antipsychotics, the C-SSRS suicide risk assessment with safety plan, the off-label prescribing acknowledgment when applicable, the discontinuation plan and refill protocol, and the e-signature audit trail under ESIGN. Each step is one paragraph of working guidance. Estimated time end-to-end: 45 minutes from blank document to signed PDF using an AI form builder. Formfy is the AI form builder psychiatric medication-management practices use to ship complete intake packets in one workflow.
Before you start, gather six pieces of information: (1) the prescriber state license, NPI, DEA registration, and state controlled-substance certification, (2) the medications commonly prescribed by schedule (Schedule II to V) and any FDA boxed warnings applicable, (3) the lab vendor or in-office collection protocol with standing-order forms for monitoring labs, (4) the practice safety-plan template and the local crisis resources (988, mobile crisis team, nearest emergency department), (5) the EHR and EPCS-capable e-prescribing platform name and BAA execution date, and (6) the e-signature platform name and BAA execution date. With those six inputs, the substantive drafting takes under 45 minutes.
Step 1: Confirm prescriber license, DEA registration, and state controlled-substance certification
The first step is to verify the prescriber credentials disclosed on the intake. Psychiatric medication-management practices typically include psychiatrists (MD/DO), Psychiatric Mental Health Nurse Practitioners (PMHNPs), and physician assistants with psychiatric scope. Each prescriber must hold an active state medical or APRN/PA license in the state where the patient is physically located at the time of the encounter. Each prescriber prescribing controlled substances must hold an active DEA registration. Some states require additional state controlled-substance certification (e.g., New York Bureau of Narcotic Enforcement registration) on top of the federal DEA. Confirm the state-of-license, the NPI, the DEA registration with the practice address on record, and any state controlled-substance certification before drafting the intake.
Step 2: Add the diagnosis and medication rationale block
Psychotropic informed consent under the American Psychiatric Association Practice Guideline framework requires disclosure of the diagnosis (using DSM-5-TR or ICD-10 nomenclature) and the rationale for medication. The intake should capture a diagnosis field (or pull from the EHR), the proposed medication name (generic and brand), the dose range, and the titration approach. The medication rationale should reference the published evidence base supporting the use, especially for off-label prescribing where the medication is FDA-approved for a different indication. Document the comparator (alternative medications considered), the prior-medication trial history if any, and the patient-stated treatment goals. The block becomes part of the audit trail proving informed consent was complete.
Step 3: Add the FDA black-box warning acknowledgment block
Many commonly prescribed psychotropics carry FDA boxed warnings. SSRIs and SNRIs carry the suicidality boxed warning for patients aged 18 to 24 (and pediatric for SSRIs). Atypical antipsychotics carry the boxed warning for increased mortality in elderly patients with dementia-related psychosis. Clozapine carries multiple boxed warnings: agranulocytosis, seizures, myocarditis, orthostatic hypotension. Typical antipsychotics carry the tardive dyskinesia warning. Benzodiazepines carry the concomitant opioid use warning. Mood stabilizers carry teratogenicity warnings. The intake should include explicit acknowledgment of all boxed warnings applicable to the proposed regimen, the monitoring protocol, and the patient or guardian commitment to report new or worsening symptoms. For under-25 patients on antidepressants, the suicidality monitoring protocol must be explicit.
Step 4: Disclose DEA Schedule II prescribing and PDMP query
For practices prescribing Schedule II controlled substances (stimulants for ADHD, dextroamphetamine, methylphenidate, lisdexamfetamine), the intake should disclose the practitioner DEA registration, the schedules covered, and the state-specific prescribing protocol. Most states require prescribers to query the Prescription Drug Monitoring Program (PDMP) before issuing a Schedule II to V prescription. Some states require integration with the EHR. The intake should include a separate consent block for PDMP query (where required), the Schedule II prescribing protocol (typically 30-day supply with no automatic refills, requiring a new prescription for each fill), and the diversion-prevention reminder (no sharing of medication, secure storage, no replacement for lost or stolen pills without police report).
Step 5: Address Ryan Haight Act and 2023 DEA telehealth final rule
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (21 U.S.C. 829(e)) generally requires an in-person medical evaluation before a controlled substance can be prescribed via telehealth, with limited exceptions. During the COVID-19 public health emergency, the DEA waived the in-person requirement, allowing controlled-substance prescribing via telehealth. The DEA published a final rule in 2023 governing the post-PHE framework, with extensions and additional rulemaking through 2024 and 2025. The current framework continues a temporary flexibility for certain controlled-substance prescribing via telehealth without an in-person visit, with requirements that vary by schedule. The intake should disclose the practitioner telehealth controlled-substance protocol and reference the current DEA rule. For buprenorphine for opioid use disorder, the framework differs (carveout for OUD prescribing).
Step 6: Add the lab monitoring schedule acknowledgment
Lab monitoring requirements vary by medication and are codified in FDA labeling and clinical practice guidelines. Lithium requires baseline and periodic renal function (BUN, creatinine), thyroid function (TSH), and serum lithium level (typically every 3 to 6 months at steady state, more often after dose changes). Valproate requires baseline and periodic complete blood count, liver function tests, and valproate level. Clozapine requires weekly absolute neutrophil count for the first 6 months, then biweekly for 6 months, then monthly. Atypical antipsychotics require baseline and periodic metabolic monitoring (weight, fasting glucose, fasting lipids, blood pressure). The intake should capture the patient acknowledgment of the monitoring schedule, the lab vendor or in-office collection protocol, and the patient commitment to follow the schedule.
Step 7: Add the suicide risk assessment block
A standardized suicide risk assessment is best practice for psychiatric prescribers. The Columbia Suicide Severity Rating Scale (C-SSRS) is widely used and short enough to integrate into intake. The SAFE-T framework (Suicide Assessment Five-step Evaluation and Triage) is a complementary structured approach. The intake should ask about current suicidal ideation, intent, plan, prior attempts, lethal means access (especially firearms), risk factors (substance use, agitation, hopelessness, recent loss, family history), and protective factors. Document the risk level (low, moderate, high) and the safety plan. For high-risk patients, the intake should trigger same-session safety planning, lethal-means counseling, and consideration of higher level of care. The Joint Commission has issued risk-assessment standards for behavioral-health settings.
Step 8: Add the off-label prescribing acknowledgment when applicable
Off-label prescribing is the practice of prescribing an FDA-approved medication for an indication, age group, dose, or route not specifically approved by the FDA. Off-label prescribing is legal and often standard of care in psychiatry: gabapentin for anxiety, prazosin for PTSD nightmares, clonidine for ADHD adjunct, propranolol for performance anxiety, low-dose naltrexone for various indications. The standard-of-care expectation is that the prescriber documents the rationale, the published evidence base supporting the off-label use, and the patient informed consent specific to the off-label nature of the prescription. The intake should include an off-label acknowledgment block when the prescriber anticipates off-label use, with explicit patient understanding that the medication is approved by the FDA for a different indication.
Step 9: Add the discontinuation plan and refill protocol
Psychotropic informed consent should disclose the discontinuation plan. Some psychotropics require gradual taper to avoid withdrawal or rebound symptoms (paroxetine, venlafaxine, benzodiazepines, certain antipsychotics). Abrupt discontinuation of these medications is medically inappropriate. The intake should disclose the typical taper schedule and the patient commitment to discuss any planned discontinuation with the prescriber before stopping the medication. The refill protocol should disclose: how many refills are typical for non-controlled medications, that controlled-substance prescriptions require a new prescription each fill, the practice protocol for after-hours refill requests, and the practice protocol for early refill requests (typically denied except for documented loss with police report). Document the protocol in the chart record.
Step 10: Confirm e-signature workflow and audit trail
The federal Electronic Signatures in Global and National Commerce Act (ESIGN Act) at 15 U.S.C. 7001 and the Uniform Electronic Transactions Act (UETA), adopted in 49 states, give electronic signatures the same legal effect as wet-ink signatures for nearly all consumer and professional services contracts. Psychiatric medication intake and informed consent are squarely covered. Use an e-signature workflow that produces a tamper-evident audit trail with timestamp, IP address, and consent-to-electronic-records affirmation. The platform must be HIPAA-compliant and operate under a Business Associate Agreement under 45 CFR 164.314 because the consent contains protected health information. The DEA generally requires a separate Electronic Prescribing of Controlled Substances (EPCS) workflow with two-factor authentication for the actual controlled-substance transmission; the patient intake and informed consent can still be e-signed under ESIGN. Store the signed packet (informed consent, controlled-substance agreement, FDA black-box warning acknowledgments, lab monitoring acknowledgment, suicide risk assessment, safety plan) in a HIPAA-compliant system retrievable on 24-hour notice.
Free template and downloadable PDF
Formfy ships a psychiatric medication intake template that maps one-to-one to the ten steps in this guide. The template is editable in the AI form builder: describe the prescriber license type, the medication scope, and the lab monitoring schedule and the builder returns a delivery-ready packet with the psychotropic informed consent, FDA boxed-warning acknowledgments for the proposed regimen, controlled- substance prescribing protocol, PDMP query consent, lab monitoring schedule, C-SSRS suicide risk assessment, safety plan, off-label prescribing block, and the e-signature block.
See also: /faq/psychiatric-medication-management-psychiatric-medication-intake for the FAQ companion hub covering 16 of the most common psychiatric medication intake questions.
Related resources
Build a psychiatric medication intake in 45 seconds
Free 15-day Formfy trial. No credit card. Submission-based pricing.
Start your free trialLast verified: 2026-04-25. This page is informational; it is not legal or clinical advice. Psychiatric medication-management practices should review state-specific controlled-substance prescribing rules, FDA labeling for the proposed medication regimen, current DEA telehealth rule, and Prescription Drug Monitoring Program mandatory-query rules with counsel and the relevant licensing board.